Clinical Trial Update: A Dose-Finding Study of AG-348 in Sickle Cell Disease [EARLY_Phase 1]

View source ↗

Summary

Early-phase dose-finding trial of AG-348 in sickle cell disease completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• AG-348 (mitapivat)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Sickle Cell Disease | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2022-07-12